Our research focuses on novel cancer preventative and therapeutic strategies targeting the ErbB2-overexpressing/ErbB2-positive (ErbB2+) breast cancer subtype, which is associated with poor prognosis and therapeutic resistance [27, 28]. The gene discussed is ERBB2; the disease is breast carcinoma.